FDA approves Tercica's growth disorder drug

The FDA has approved Tercica's Somatuline Autogel, an injectable treatment for adult patients with acromegaly. Acromegaly is a rare disorder caused by too much growth hormone, resulting in enlarged body tissues of the face, jaw, hands, feet and skull. The approval is good news for Ipsen; last year the company granted Tercica development and commercialization rights to the drug, and Ipsen will gain a $41 million milestone payment from Tercica.

- see this press release for more